Skip to main content

Market Overview

Merck/Ridgeback Biotherapeutics' COVID-19 Antiviral Shows Promise


Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics LP reported preliminary results from Phase 2a study evaluating molnupiravir, an experimental antiviral drug against COVID-19.

  • The antiviral has shown positive effects with a significant reduction in the infectious virus in COVID-19 patients after five days of treatment.
  • If results from further ongoing testing show the drug can treat COVID-19 patients exhibiting symptoms, it could be the first oral antiviral to fight the infection, the Wall Street Journal reports.
  • The full study results remain blinded and will be shared later as they become available.
  • Merck is also working on one more COVID-19 treatment called MK-711.
  • The first results of the trials show a reduction of more than 50% in the risk of death or respiratory failure in hospitalized patients.
  • Last month, it announced that the FDA asked for additional data beyond the study conducted by OncoImmune.
  • Price Action: MRK shares are trading 0.92% higher at $73.80 in premarket on the last check Monday.

Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: Covid-19 Phase 2A Trial Wall Street JournalBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at